Overview
rs10012 is a genetic variant on gene CYP1B1 associated with Anterior segment dysgenesis 6 and Congenital glaucoma.
This variant is located on chromosome 2. The variations at position 38075247 are the genetic letters C/C, G/G, C/G
Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation combination is referred to as genotype. For variant rs10012 there are 3 currently known genotypes : C/C, G/G or C/G
Short Overview
Variant Location
rs10012 is located on gene CYP1B1 in chromsome 2. Use the genome browser to explore the location of rs10012 and its genetic neighbourhood.
Conditions & Traits
rs10012 affects the following conditions and traits:
Pathogenicity
rs10012 affects the following conditions:
Genome Browser
This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant rs on gene CYP1B1. Explore more variants and their effects on the body by browsing left and right along the DNA strand.
Did you know genetic variants affect drugs?
Mutations are changes in genes and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.
Conditions & Traits of rs10012
The different genotypes of variant rs10012 can affect the likelyhood of developing certain traits or conditions. Current research shows that 2 conditions and 0 traits are associated with rs10012. The following table shows the relationship between genotypes and conditions and traits.
Classification of Variants
Variants can be classified either based on scientific studies or clinical tests. Scientific studies classifications aim to uncover the function of genetic variants and their role in conditions, traits, and evolution. Variants are categorized according to their functional effect, such as loss-of-function (reduced gene activity), gain-of-function (increased gene activity), neutral (no significant impact) or evolutionary conservation. This classification uses experimental data, population studies, and computational analyses to understand the long-term effects of variants. Clinical testing classifications, however, focus on the immediate health impact on the human body, distinguishing five categories from disease causing (harmful) to no effect (not harmful). This classification relies on a mix of family history, lab tests, and computer predictions, aiming to assist doctors in making medical decisions.
Conditions
2Genotype
C
C
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters C/C is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
G
G
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters G/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
C
G
Level of evidence
Sources
No effect
Unisex
1 Sources
Participants: 0
The genotype with the letters C/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Pharmacogenetics
The genetic variant rs10012 impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with rs10012. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.
Genotype
Level of evidence
Impacts
Summary
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/C have decreased Drug Effect to RISPERIDONE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype C/G have decreased Drug Effect to RISPERIDONE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have increased Drug Effect to RISPERIDONE.
more info
Legend:
Increased
Decreased
No known effect
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/C have decreased Drug Effect to RISPERIDONE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype C/G have decreased Drug Effect to RISPERIDONE.
Level of evidence
More info
Genotype
Impacts
Breakdown
Drug Effect
Side Effects
Dosage
Summary
Individuals with the genotype G/G have increased Drug Effect to RISPERIDONE.
Level of evidence
More info
Legend:
Increased
Decreased
No known effect
Drugs related to rs10012
All drugs that are linked to rs10012 are listed here.
Studies and Sources
All of the resources below examine variant rs10012
Junjun Wang, Qingyun Liu, Shuai Yuan, Weijia Xie, Yuan Liu, Ying Xiang, Na Wu, Long Wu, Xiangyu Ma, Tongjian Cai, Yao Zhang, Zhifu Sun, Yafei Li
Nana Li, Yi Mu, Zhen Liu, Ying Deng, Yixiong Guo, Xuejuan Zhang, Xiaohong Li, Ping Yu, Yanping Wang, Jun Zhu
Yar Muhammad Waryah, Muhammad Iqbal, Shakeel Ahmed Sheikh, Muhammad Azhar Baig, Ashok Kumar Narsani, Muhammad Atif, Munir Ahmad Bhinder, Attiq Ur Rahman, Azam Iqbal Memon, Muhammad Suleman Pirzado, Ali Muhammad Waryah